# Sacha Lainovic

> Sacha Lainovic is a Series A investor at Invus backing Baby and Wellness. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Invus](https://shizune.co/investors/profile/invus)
- Total investments: 2
- Last investment: Feb 2020
- Lead investor: 0%
- Last updated: Aug 2026

Sacha Lainovic is a Series A investor at Invus focused on Baby and Wellness. Sacha Lainovic is Managing Director & prior to co-founding Invus Opps, Sacha was a co-founder and the Executive Vice President of the Invus Group from 1985-2006. Prior to Invus, Sacha was a manager at The Boston Consulting Group in Paris. Sacha holds an M.S. from INSA de Lyon and an MBA from Stanford University. He serves on the Boards of theMetropolitan Museum of Art, the Hospital for Special Surgery and is a member of the Stanford Graduate School of Business Advisory Council.

## Contacts

5 contacts available for Sacha Lainovic: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/sacha-lainovic?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Baby | 1 | 50% |
| Wellness | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Consumer Goods | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series C | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alladapt Immunotherapeutics | Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens. | $60M | Series C | Feb 20, 2020 |  |
| BEFORE Brands | The immune system: part soldier, part sentinel. An essential balance, perfected by time but increasingly disrupted by modern living. BEFORE Brands is developing edible products to support this critical duality, beginning in healthy infants before problems arise. Our products use our proprietary Early Adaptive Tolerance blend of whole food proteins& Vitamin D designed to help provide balanced, gentle & consistent immune system training right from the start. This technology was innovated by Dr. Kari Nadeau, a pediatrician, mother of five, and the Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. Our products build on a growing body of evidence in support of nutritional strategies that include potentially allergenic foods as a regular part of a healthy diet. |  | Series A | Oct 05, 2016 |  |

2 of 2 investments shown.

## Co-investors
- Camino Partners — VC Fund, 2 deals together
- [Gurnet Point Capital](https://shizune.co/investors/profile/gurnet-point-capital) — VC Fund, 2 deals together
- [TRB Advisors](https://shizune.co/investors/profile/trb-advisors) — VC Fund, 1 deal together

## About Invus

VC Fund · New York, United States

Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic approach. Due to their unique structure, they have a great deal of flexibility in the types of companies and situations where they can get involved.They know that real transformation takes time and that it is nevera straight line. They fully align their incentives with their partners and have the wherewithal and long-term commitment to see through any bumps along the way.They have been successfully empowering owner-managers since 1985. They have been reinvesting the same pool of money from the same group of European families (through their Artal investment vehicle) since their founding. Today they manage over $4 billion in an evergreen fund and work out of offices in New York, London, Paris and Hong Kong.

5 contacts available at Invus.

| Name | Title | Profile |
| --- | --- | --- |
| Benedetto Staccia | Managing Director | https://shizune.co/investors/profile/benedetto-staccia |
| Christopher Marsh | Private Equity Senior Associate | https://shizune.co/investors/profile/christopher-marsh |
| Evren Bilimer | Managing Director | https://shizune.co/investors/profile/evren-bilimer |
| Addy Ho | Vice President | https://shizune.co/investors/profile/addy-ho |
| Benjamin Tsai | Partner | https://shizune.co/investors/profile/benjamin-tsai |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Sacha Lainovic invest in?

Sacha Lainovic invests primarily in Baby, Wellness and Health Care startups, most often at Series A and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sacha Lainovic?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Sacha Lainovic last invest?

The most recent investment recorded for Sacha Lainovic closed in Feb 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co